Suggested remit: To appraise the clinical and cost effectiveness of pirtobrutinib for untreated chronic lymphocytic leukaemia or small lymphocytic lymphoma.
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Process:
- STA Standard
- ID number:
- 6397
Provisional Schedule
- Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators:
- 14 January 2026 - 11 February 2026
Project Team
- Project lead
- Emily Richards
Email enquiries
If you have any queries please email scopingta@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 14 October 2024 | Please note that following on from advice received from the company this appraisal has been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin during early March 2026 when we will write to you about how you can get involved. The deadline for submissions is expected in approximately mid-May 2026. |
| 08 August 2024 | Please note that following on from advice received from the company this appraisal has been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin during late October 2025 when we will write to you about how you can get involved. The deadline for submissions is expected in approximately mid-January 2026. |
| 14 February 2024 | In progress. Scoping commenced. |
| 30 January 2024 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
| 30 January 2024 | Topic selection |
For further information on our processes and methods, please see our CHTE processes and methods manual